Cargando…
Myocarditis after RNA-based vaccines for coronavirus.
BACKGROUND: The incidence of myocarditis after RNA-based vaccines for coronavirus has gained social and medical interest. METHODS: We performed an intention-to-treat meta-analysis, following the PRISMA statement. After a systematic search, without language restriction, 9 publications were selected....
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8782727/ https://www.ncbi.nlm.nih.gov/pubmed/35074491 http://dx.doi.org/10.1016/j.ijcard.2022.01.037 |
_version_ | 1784638374071500800 |
---|---|
author | Cordero, Alberto Cazorla, Diego Escribano, David Quintanilla, Mª. Amparo López-Ayala, José Mª. Berbel, Patricio Pérez Bertomeu-González, Vicente |
author_facet | Cordero, Alberto Cazorla, Diego Escribano, David Quintanilla, Mª. Amparo López-Ayala, José Mª. Berbel, Patricio Pérez Bertomeu-González, Vicente |
author_sort | Cordero, Alberto |
collection | PubMed |
description | BACKGROUND: The incidence of myocarditis after RNA-based vaccines for coronavirus has gained social and medical interest. METHODS: We performed an intention-to-treat meta-analysis, following the PRISMA statement. After a systematic search, without language restriction, 9 publications were selected. Two were excluded (one was only in subjects with age 12–17 and other might had included subjects from a larger publication). We followed the PRISMA guidelines for abstracting data and assessing data quality and validity. Data was verified by 2 investigators. RESULTS: We analyzed 17,704,413 subjects, from 7 studies, that included 627 cases of confirmed myocarditis). The incidence of myocarditis was 0.0035% (95% CI 0.0034–0.0035). Mean incidence rate was 10.69 per 100.000 persons-year. Cases reported from Israel represented 45.14% from total (283 out of the 627). Only 1 case of fatal myocarditis or death was reported. There was significant heterogeneity between results. The meta-regression analysis excluded mean age, region, number of cases or number of people included as sources of heterogeneity. No small-study effect was observed (p = 0.19). CONCLUSIONS AND RELEVANCE: Myocarditis incidence after RNA vaccines is very rare (0.0035%) and has a very favorable clinical course. |
format | Online Article Text |
id | pubmed-8782727 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87827272022-01-24 Myocarditis after RNA-based vaccines for coronavirus. Cordero, Alberto Cazorla, Diego Escribano, David Quintanilla, Mª. Amparo López-Ayala, José Mª. Berbel, Patricio Pérez Bertomeu-González, Vicente Int J Cardiol Short Communication BACKGROUND: The incidence of myocarditis after RNA-based vaccines for coronavirus has gained social and medical interest. METHODS: We performed an intention-to-treat meta-analysis, following the PRISMA statement. After a systematic search, without language restriction, 9 publications were selected. Two were excluded (one was only in subjects with age 12–17 and other might had included subjects from a larger publication). We followed the PRISMA guidelines for abstracting data and assessing data quality and validity. Data was verified by 2 investigators. RESULTS: We analyzed 17,704,413 subjects, from 7 studies, that included 627 cases of confirmed myocarditis). The incidence of myocarditis was 0.0035% (95% CI 0.0034–0.0035). Mean incidence rate was 10.69 per 100.000 persons-year. Cases reported from Israel represented 45.14% from total (283 out of the 627). Only 1 case of fatal myocarditis or death was reported. There was significant heterogeneity between results. The meta-regression analysis excluded mean age, region, number of cases or number of people included as sources of heterogeneity. No small-study effect was observed (p = 0.19). CONCLUSIONS AND RELEVANCE: Myocarditis incidence after RNA vaccines is very rare (0.0035%) and has a very favorable clinical course. Elsevier B.V. 2022-04-15 2022-01-22 /pmc/articles/PMC8782727/ /pubmed/35074491 http://dx.doi.org/10.1016/j.ijcard.2022.01.037 Text en © 2022 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Short Communication Cordero, Alberto Cazorla, Diego Escribano, David Quintanilla, Mª. Amparo López-Ayala, José Mª. Berbel, Patricio Pérez Bertomeu-González, Vicente Myocarditis after RNA-based vaccines for coronavirus. |
title | Myocarditis after RNA-based vaccines for coronavirus. |
title_full | Myocarditis after RNA-based vaccines for coronavirus. |
title_fullStr | Myocarditis after RNA-based vaccines for coronavirus. |
title_full_unstemmed | Myocarditis after RNA-based vaccines for coronavirus. |
title_short | Myocarditis after RNA-based vaccines for coronavirus. |
title_sort | myocarditis after rna-based vaccines for coronavirus. |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8782727/ https://www.ncbi.nlm.nih.gov/pubmed/35074491 http://dx.doi.org/10.1016/j.ijcard.2022.01.037 |
work_keys_str_mv | AT corderoalberto myocarditisafterrnabasedvaccinesforcoronavirus AT cazorladiego myocarditisafterrnabasedvaccinesforcoronavirus AT escribanodavid myocarditisafterrnabasedvaccinesforcoronavirus AT quintanillamaamparo myocarditisafterrnabasedvaccinesforcoronavirus AT lopezayalajosema myocarditisafterrnabasedvaccinesforcoronavirus AT berbelpatricioperez myocarditisafterrnabasedvaccinesforcoronavirus AT bertomeugonzalezvicente myocarditisafterrnabasedvaccinesforcoronavirus |